Compare Peptides
Select any two compounds for a side-by-side comparison of mechanism, uses, risks, and FDA regulatory status.
Popular comparisons
LL-37
Cathelicidin, Human Cathelicidin Antimicrobial Peptide
The only human cathelicidin antimicrobial peptide, LL-37 is a 37-amino-acid peptide naturally produced by immune cells, epithelial cells, and barrier tissues. It plays a critical role in innate immunity by directly killing bacteria, viruses, and fungi, while also modulating inflammatory responses. Increasingly studied for chronic infections, biofilm disruption, and immune regulation.
A thymic peptide that plays a central role in immune system regulation. Approved as a drug in over 35 countries (though not in the US) for hepatitis B and C treatment and as an immune booster.
Disrupts microbial membranes through electrostatic interaction with negatively charged bacterial surfaces, creating pores that kill pathogens. Also modulates immune responses by recruiting immune cells, promoting wound healing, and disrupting bacterial biofilms. Acts as a bridge between innate and adaptive immunity.
Enhances T-cell function, promotes dendritic cell maturation, and modulates cytokine production. Acts as an immune system regulator rather than a simple stimulant, helping to balance immune responses.
- Immune system support
- Chronic infection management
- Biofilm disruption (Lyme, SIBO)
- Wound healing
- Upper respiratory infection support
- Immune system support
- Chronic infection management
- Cancer adjunct therapy (in some countries)
- Post-illness recovery
- Autoimmune condition management
- Injection site reactions (pain, redness)
- Potential autoimmune activation at high doses
- Limited human clinical data for therapeutic use
- Overexpression linked to psoriasis and rosacea in some contexts
- Generally well-tolerated in clinical use
- Injection site reactions
- Rare allergic reactions
- May interact with immunosuppressive drugs
Not FDA-approved as a therapeutic. LL-37 is an endogenous human peptide being studied in clinical trials for wound healing and infection. Some compounding pharmacies have offered it, but it has no formal FDA category for compounding. Research is ongoing for topical wound applications.
Reclassified to Category 1 in February 2026 as part of the HHS announcement restoring compounding access. Not affected by the April 15, 2026 Category 2 removal action. Approved as Zadaxin in 35+ countries but not FDA-approved in the US. Available through licensed 503A compounding pharmacies with a physician prescription.
This comparison is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any peptide therapy.